News

Jonas Gileguy Konan, DMSc, PA-C: A Journey of Service, Leadership, and Lifelong Learning

Jonas Gileguy Konan’s path to becoming a respected leader in neurosurgery and a distinguished SIU DMSc alumnus began long before he stepped into an operating room. His commitment to patient care took root as an undergraduate paramedic volunteer in Houston, where he found himself deeply connected to the front lines of emergency medicine. Yet something was missing. After each patient handoff, the story ended abruptly. There was no follow-up, no continuity, and no opportunity to witness recovery. That desire to participate in the full spectrum of patient care ultimately steered him toward the PA
Trial
Internal Medicine

COSIRA-II: Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II

Active recruiting
To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization.
News

SIU Medicine launches national search for next dean, provost and CEO

Southern Illinois University Medicine has launched a national search for its next dean, provost and CEO. The search will be conducted in partnership with Isaacson, Miller, a national executive search firm specializing in academic medicine and higher education leadership.
News

SIU Medicine launches national search for next dean, provost and CEO

Southern Illinois University Medicine has launched a national search for its next dean, provost and CEO. The search will be conducted in partnership with Isaacson, Miller, a national executive search firm specializing in academic medicine and higher education leadership.
News

SIU Medicine launches national search for next dean, provost and CEO

Southern Illinois University Medicine has launched a national search for its next dean, provost and CEO. The search will be conducted in partnership with Isaacson, Miller, a national executive search firm specializing in academic medicine and higher education leadership.
News

SIU Medicine launches national search for next dean, provost and CEO

Southern Illinois University Medicine has launched a national search for its next dean, provost and CEO. The search will be conducted in partnership with Isaacson, Miller, a national executive search firm specializing in academic medicine and higher education leadership.
News

SIU Medicine launches national search for next dean, provost and CEO

Southern Illinois University Medicine has launched a national search for its next dean, provost and CEO. The search will be conducted in partnership with Isaacson, Miller, a national executive search firm specializing in academic medicine and higher education leadership.
News

Ginger Meyer honored for leadership in trauma recovery

Ginger Meyer has spent more than twenty years helping children and families in southern Illinois heal from trauma, earning national recognition from the Academy on Violence and Abuse. As clinical director of SIU School of Medicine’s Children’s Medical and Mental Health Resource Network, she has expanded access to trauma-informed care in rural communities and kept families at the center of the work.
News

Ginger Meyer honored for leadership in trauma recovery

Ginger Meyer has spent more than twenty years helping children and families in southern Illinois heal from trauma, earning national recognition from the Academy on Violence and Abuse. As clinical director of SIU School of Medicine’s Children’s Medical and Mental Health Resource Network, she has expanded access to trauma-informed care in rural communities and kept families at the center of the work.
Trial
Cardiology

Dal-GenE-2: A phase 3, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)

Active recruiting
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.
Subscribe to